Boston Life, Zeneca Group plc deal

BLSI (Waltham, Mass.) and Zeneca (London) will develop small molecule inhibitors of major histocompatibility complex ( MCH) Class II gene transcription to treat autoimmune diseases. BLSI will receive ...